中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
4期
487-488
,共2页
膜性肾病%尿蛋白%参芎葡萄糖注射液
膜性腎病%尿蛋白%參芎葡萄糖註射液
막성신병%뇨단백%삼궁포도당주사액
Membranous nephropathy%Urine protein%Shenxiong glucose injection
目的 观察参芎葡萄糖注射液治疗膜性肾病的疗效及对血液流变学的影响.方法 选择我院经肾活检证实为特发性膜性肾病的住院患者40例,完全随机分成参芎组和常规治疗组,各20例.2组患者均给予常规治疗,参芎组在常规治疗基础上加用参芎葡萄糖注射液200 ml静脉滴注,1次/d,14 d为1个疗程.患者均于治疗前后进行24h尿蛋白定量、血脂、纤维蛋白原(Fib)、红细胞压积(HCT)测定,比较2组疗效.结果 参芎组与常规治疗组治疗后尿蛋白均明显下降(P＜0.05),但2组间比较差异无统计学意义(P＞0.05).参芎组治疗后TG、TC、LDL-C、Fib及HCT下降明显[(7.3±1.3) mmol/L比(8.1±1.3) mmol/L,(2.1±0.5)mmol/L比(2.5 ±0.4)mmol/L,(2.2 ±0.7)mmol/L比(3.1 ±0.8)mmol/L,(4.6±0.7)g/L比(5.9±0.8)g/L,(38±3)％比(45±5)％](均P＜0.05),而常规治疗组各项指标改善不明显(P＞0.05),参芎组和常规治疗组治疗后TG、TC、LDL-C、Fib及HCT比较差异有统计学意义[7.3±1.3) mmol/L比(7.9±1.1)mmol/L,(2.1 ±0.5)mmol/L比(2.3±0.4)mmol/L,(2.2±0.7)mmol/L比(3.3±0.6) mmol/L,(4.6±0.7)g/L比(5.9±0.6)g/L,(38±3)％比(43±4)％,均P＜0.05].常规治疗组患者中3例(15.0％)出现下肢深静脉血栓,参芎组无此并发症出现,2组并发病发生率比较差异有统计学意义(P＜0.05).结论 参芎葡萄糖注射液能有效改善膜性肾病患者微循环,降低血脂和血黏度,安全有效.
目的 觀察參芎葡萄糖註射液治療膜性腎病的療效及對血液流變學的影響.方法 選擇我院經腎活檢證實為特髮性膜性腎病的住院患者40例,完全隨機分成參芎組和常規治療組,各20例.2組患者均給予常規治療,參芎組在常規治療基礎上加用參芎葡萄糖註射液200 ml靜脈滴註,1次/d,14 d為1箇療程.患者均于治療前後進行24h尿蛋白定量、血脂、纖維蛋白原(Fib)、紅細胞壓積(HCT)測定,比較2組療效.結果 參芎組與常規治療組治療後尿蛋白均明顯下降(P＜0.05),但2組間比較差異無統計學意義(P＞0.05).參芎組治療後TG、TC、LDL-C、Fib及HCT下降明顯[(7.3±1.3) mmol/L比(8.1±1.3) mmol/L,(2.1±0.5)mmol/L比(2.5 ±0.4)mmol/L,(2.2 ±0.7)mmol/L比(3.1 ±0.8)mmol/L,(4.6±0.7)g/L比(5.9±0.8)g/L,(38±3)％比(45±5)％](均P＜0.05),而常規治療組各項指標改善不明顯(P＞0.05),參芎組和常規治療組治療後TG、TC、LDL-C、Fib及HCT比較差異有統計學意義[7.3±1.3) mmol/L比(7.9±1.1)mmol/L,(2.1 ±0.5)mmol/L比(2.3±0.4)mmol/L,(2.2±0.7)mmol/L比(3.3±0.6) mmol/L,(4.6±0.7)g/L比(5.9±0.6)g/L,(38±3)％比(43±4)％,均P＜0.05].常規治療組患者中3例(15.0％)齣現下肢深靜脈血栓,參芎組無此併髮癥齣現,2組併髮病髮生率比較差異有統計學意義(P＜0.05).結論 參芎葡萄糖註射液能有效改善膜性腎病患者微循環,降低血脂和血黏度,安全有效.
목적 관찰삼궁포도당주사액치료막성신병적료효급대혈액류변학적영향.방법 선택아원경신활검증실위특발성막성신병적주원환자40례,완전수궤분성삼궁조화상규치료조,각20례.2조환자균급여상규치료,삼궁조재상규치료기출상가용삼궁포도당주사액200 ml정맥적주,1차/d,14 d위1개료정.환자균우치료전후진행24h뇨단백정량、혈지、섬유단백원(Fib)、홍세포압적(HCT)측정,비교2조료효.결과 삼궁조여상규치료조치료후뇨단백균명현하강(P＜0.05),단2조간비교차이무통계학의의(P＞0.05).삼궁조치료후TG、TC、LDL-C、Fib급HCT하강명현[(7.3±1.3) mmol/L비(8.1±1.3) mmol/L,(2.1±0.5)mmol/L비(2.5 ±0.4)mmol/L,(2.2 ±0.7)mmol/L비(3.1 ±0.8)mmol/L,(4.6±0.7)g/L비(5.9±0.8)g/L,(38±3)％비(45±5)％](균P＜0.05),이상규치료조각항지표개선불명현(P＞0.05),삼궁조화상규치료조치료후TG、TC、LDL-C、Fib급HCT비교차이유통계학의의[7.3±1.3) mmol/L비(7.9±1.1)mmol/L,(2.1 ±0.5)mmol/L비(2.3±0.4)mmol/L,(2.2±0.7)mmol/L비(3.3±0.6) mmol/L,(4.6±0.7)g/L비(5.9±0.6)g/L,(38±3)％비(43±4)％,균P＜0.05].상규치료조환자중3례(15.0％)출현하지심정맥혈전,삼궁조무차병발증출현,2조병발병발생솔비교차이유통계학의의(P＜0.05).결론 삼궁포도당주사액능유효개선막성신병환자미순배,강저혈지화혈점도,안전유효.
Objective To observe the clinical effect and the influence of hemorheology of Shenxiong glucose injection for patients with membranous nephropathy.Methods Forty inpatients with membranous nephropathy were chosen and divided to the Shenxiong group and conventional therapy group (20 cases each group).All patients received conventional therapy.The Shenxiong group were given Shenxiong glucose injection by intravenous infusions (200 ml/d for 14 days).Twenty-four hours urinary protein excretion,blood lipids,fibrinogen (Fib),hematocrit (HCT) measurement were measured before and after treatment,and the efficacy of the two groups were compared.Results Urinary protein decreased significantly after treatment in the Shenxiong group and the conventional therapy group (P ＜ 0.05),but the difference was not statistically significant (P ＞ 0.05).Triglyceride (TG),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C),HCT and Fib in Shenxiong group after treatment decreased significantly [(7.3 ± 1.3) mmol/L vs (8.1 ± 1.3) mmol/L,(2.1 ± 0.5) mmol/L vs (2.5 ± 0.4) mmol/L,(2.2 ±0.7)mmol/L vs (3.1 ±0.8)mmol/L,(4.6 ±0.7)g/L vs (5.9 ±0.8)g/L,(38 ±3)％ vs (45 ±5)％](P ＜ 0.05),whereas the indicators had little improvement in the conventional therapy group (P ＞ 0.05),and the difference between two groups was statistically significant (P ＜ 0.05).Three cases (15.0％) occurred deep venous thrombosis in conventional therapy group,while no such complications occurred in the Shenxiong group.The difference was statistically significant (P ＜ 0.05).Conclusion Shenxiong glucose injection can improve the microcirculation and decrease blood lipid and blood viscosity of patients with membranous nephropathy.It is safe and effective and suitable promotion.
